Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02399137 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

A Phase 2 study of Pancreatic Cancer, sponsored by Merrimack Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT02399137: Completed Phase 2 study of Pancreatic Cancer, sponsored by Merrimack Pharmaceuticals.

NCT02399137 is a Phase 2 study of Pancreatic Cancer that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 88 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02399137, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Merrimack Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG Placebo
  • DRUG Nab-Paclitaxel
  • DRUG Gemcitabine
  • DRUG MM-141

Study Locations (20)

California

  • Pacific Cancer Medical Center, Inc. - Anaheim
  • St. Jude Heritage Healthcare - Fullerton
  • UCLA School of Medicine - Los Angeles
  • Cancer Care Assoc Med Grp - Redondo Beach
  • UCSF Cancer Center - San Francisco
  • Sansum Clinic - Santa Barbara
  • Central Coast Med Onc Corp - Santa Maria

Illinois

  • Northwestern University - Chicago
  • University of Illinois at Chicago - Chicago
  • Illinois Cancer Specialists - Chicago
  • Oncology Specialists, S.C. - Park Ridge
  • Midwest Regional Medical Cntr - Zion

Florida

  • Baptist Health Med Gr Onc, LLC - Miami
  • Florida Cancer AffiliatesOcala - Ocala
  • Memorial Regional Hospital - Pembroke Pines

Arizona

  • Banner MD Anderson Cancer Ctr. - Gilbert

Colorado

  • Rocky Mountain Cancer Centers - Aurora

Georgia

  • Cancer Treatment Centers of America-Georgia - Newnan

Iowa

  • Nylen Cancer Center - Sioux City

Louisiana

  • Cancer Center of Acadiana Research Department - Lafayette

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2015-05
Est. Completion 2018-08
Phase Phase 2
Merrimack Pharmaceuticals

22 total trials

What the finished NCT02399137 record still lists

NCT02399137 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT02399137 names 20 study sites across 8 states, led by California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT02399137 about?

NCT02399137 is a clinical study titled "A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer". The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-...

What is the current status of trial NCT02399137?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2015-05. Estimated completion is 2018-08.

What conditions does trial NCT02399137 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT02399137?

The interventions under investigation include: Placebo (DRUG), Nab-Paclitaxel (DRUG), Gemcitabine (DRUG), MM-141 (DRUG).

Who is sponsoring clinical trial NCT02399137?

This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02399137 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02399137's enrollment target sits among peer trials

88 114th of 278 higher than 165 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02399137, the US trial registry maintained by the National Library of Medicine. NCT02399137 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.